Abstract:Background: Cutaneous melanoma is rare in children with a global incidence of two to five cases per million people per year, accounting for roughly 1% of all pediatric malignancies.5 However, the incidence of pediatric melanoma in the United States is increasing.1 Mohs Micrographic Surgery (MMS) is a standard treatment for adult skin cancer due to its low recurrence rates and tissue preservation. However, it is less commonly used to treat melanoma in children because the required infrastructure is not widely accessible and many pediatric surgeons are not familiar with MMS.4 With more limited treatment options for pediatric melanoma, it is important to question the role of socioeconomic factors that may contribute to MMS treatment of pediatric patients with melanoma.2 Purpose: The purpose of the study is to investigate pediatric patients with melanoma and assess their tumor characteristics by comparing various skin cancer treatments (Mohs, other treatments [local excision], or no treatment).Methods: This is a retrospective cohort study of pediatric patients (age < 21 years) diagnosed with cutaneous Melanoma who received MMS between 2004 and 2020 in the National Cancer Database (NCDB). Descriptive statistics were collected on the following variables: the year of diagnosis, sex, race, tumor stage, tumor behavior, primary site, and surgical procedure. Overall survival was determined via the Kaplan-Meier test. Results: 104 cases of pediatric melanoma treated with MMS were identified. Per statistical analysis, it does not appear that surgical frequency has varied yearly from 2004 to 2020 (r2 = 0). The median age of patients analyzed was 18 years old. Most patients were female (64.4%, N = 67), White (100%, N=104), non-Hispanic (100%, N=104), and had private insurance (87.3%, N = 90). 70.2% (N=73) of cases were defined as early-stage (stage 0 or I). 72.1% (N=75) of cases were identified as invasive. 45.2% (N=47) of MMS were performed with a margin of 1 cm or less, 19.2% (N=20) were performed with a margin of 1 cm or more, and the remaining had unspecified margins. The most common primary site for MMS was skin of the trunk (33.7%, N=35), followed by the upper limb and shoulder (16.3%, N=17), and the lower limb and hip (15.4%, N=16). All patients were alive at the last contact, with a median overall survival of 182 months (15.2 years). Discussion: MMS is used commonly in adults to treat a variety of skin tumors that can have aggressive traits such as melanoma. Although it offers low recurrence rates and tissue-sparing treatment in adult populations, MMS frequency has not changed within the pediatric population. MMS is mainly seen in privately insured, White patients with an early stage of melanoma; this is likely due to lower rates and delayed diagnosis in patients with darker skin that would otherwise present with metastatic disease. Given its clinical advantages and low rate of use, further research should address barriers that affect the availability of MMS in the pediatric population. Citation Format: Zachary G. Brandt, Xinxin Wu, Jared Kennard, Julia Griffin, Peter Silberstein. Mohs surgery trends in 104 cases of pediatric melanoma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 3566.

Mohs Micrographic Surgery for Invasive Melanoma Allows for Tissue Preservation Compared With Wide Local Excision: A Retrospective Cohort Study

Mohs Micrographic Surgery in the Surgical Treatment Paradigm of Melanoma In Situ and Invasive Melanoma: A Clinical Review of Treatment Efficacy and Ongoing Controversies

Intraoperative Immunohistochemistry During Mohs Micrographic Surgery and Staged Excision Decreases Local Recurrence Rates for Invasive Cutaneous Melanoma: A Systematic Review and Meta-Analysis

micrographic surgery for invasive melanoma of the trunk and proximal portion of the extremities

Clinical Versus Histologic Margins for Cutaneous Squamous Cell Carcinoma: Comparing Outcomes for High-Risk Tumors Treated With Mohs Micrographic Surgery

Mohs micrographic surgery for the treatment of invasive melanoma: A systematic review with meta‐analyses

[Modified Mohs Micrographic Surgery in the Treatment of Cutaneous Melanoma].

A review of Mohs micrographic surgery for skin cancer. Part 1: Melanoma and rare skin cancers

Surgical Margins of Nonmelanoma Skin Cancers in Mohs Surgery: Dermoscopy Versus Naked Eye

Mohs Micrographic Surgery: A Brief Overview

Mohs micrographic technique in high-risk basal cell carcinoma: a 3D prediction of safety margins

Using optical coherence tomography to optimize Mohs micrographic surgery

Mohs micrographic surgery for eyelid sebaceous carcinoma: A multicenter cohort of 360 patients.

Excision Margins for Melanoma in Situ on the Head and Neck – A Single-Center 10-year Retrospective Review of Treatment with Mohs Micrographic Surgery

Disease-Specific Mortality of Dermatofibrosarcoma Protuberans After Mohs Surgery Versus Wide Local Excision: A Systematic Review and Meta-analysis

Abstract 3566: Mohs surgery trends in 104 cases of pediatric melanoma

Establishing Consensus for Mohs Micrographic Surgical Techniques in the Treatment of Melanoma in Situ for Future Clinical Trials: A Modified Delphi Study

Enhanced Disease-Specific Survival Among Individuals With Malignant Adnexal Tumors of the Skin Treated With Mohs Surgery: A National Database Study

Factors Influencing Margin Clearance and the Number of Stages of Mohs Micrographic Surgery in Basal Cell Carcinoma: A Retrospective Chart Review

Prognostic Significance of Tumor Size for Primary Invasive Cutaneous Melanoma: A Population‐based Study, 2004‐2016

Recurrence Rate of Melanoma In Situ Excised With a 5-mm Excisional Margin